Symptom severity following rifaximin and the probiotic vsl#3 in patients with chronic pelvic pain syndrome (Due to inflammatory prostatitis) plus irritable bowel syndrome

Enzo Vicari, Michele Salemi, Giuseppe Sidoti, Mariano Malaguarnera, Roberto Castiglione

Research output: Contribution to journalReview articlepeer-review

9 Downloads (Pure)

Abstract

This study investigated the effects of long-term treatment with rifaximin and the probiotic VSL#3 on uro-genital and gastrointestinal symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) plus diarrhoea-predominant irritable bowel syndrome (D-IBS) compared with patients with D-IBS alone. Eighty-five patients with CP/CPPS (45 with subtype IIIa and 40 with IIIb) plus D-IBS according to the Rome III criteria and an aged-matched control-group of patients with D-IBS alone (n = 75) received rifaximin and VSL#3. The primary endpoints were the response rates of IBS and CP/CPPS symptoms, assessed respectively through Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) and The National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and performed at the start of therapy (V0) and three months after (V3). In IIIa prostatitis patients, the total NIH-CPSI scores significantly (p < 0.05) decreased from a baseline mean value of 21.2 to 14.5 at V3, as did all subscales, and in the IIIb the total NIH-CPSI score also significantly decreased (from 17.4 to 15.1). Patients with IBS alone showed no significant differences in NIH-CPSI score. At V3, significantly greater improvement in the IBS-SSS and responder rate were found in IIIa patients. Our results were explained through a better individual response at V3 in IIIa prostatitis of urinary and gastrointestinal symptoms, while mean leukocyte counts on expressed prostate secretion (EPS) after prostate massage significantly lowered only in IIIa cases.

Original languageEnglish
Article number1208
JournalNutrients
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 1 2017

Keywords

  • Chronic pelvic pain syndrome
  • Irritable bowel syndrome
  • Irritable bowel syndrome-severity scoring system
  • Probiotic VSL#3
  • Rifaximin

ASJC Scopus subject areas

  • Food Science
  • Nutrition and Dietetics

Fingerprint Dive into the research topics of 'Symptom severity following rifaximin and the probiotic vsl#3 in patients with chronic pelvic pain syndrome (Due to inflammatory prostatitis) plus irritable bowel syndrome'. Together they form a unique fingerprint.

Cite this